ArticleClinics (Sao Paulo, Brazil)2026
GSDMD/Caspase-1-based evaluation of dydrogesterone in preventing recurrence after hysteroscopic endometrial polypectomy.
Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe research focuses on understanding how GSDMD and Caspase-1, key regulators of pyroptosis, influence postoperative recurrence in Endometrial Polyps (EPs) and examines whether a combined biomarker can effectively predict recurrence likelihood.
methods264 EP patients (stratified post-surgery into dydrogesterone-treated and control groups) and 132 healthy women were included. Peripheral blood GSDMD-N, Caspase-1, and estrogen concentrations were quantified. Follow-up assessments at one-year post-operation were conducted to examine associations between these pyroptotic markers and clinical outcomes.
resultsIncreases in GSDMD-N and Caspase-1 were observed in EP patients versus healthy subjects (p < 0.05). A diagnostic AUC of 0.781 was determined for the joint model. Pyroptosis markers correlated positively with FSH//E
conclusionPost-EP recurrence correlates with GSDMD/Caspase-1 levels, and integrating these markers enhances recurrence risk assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.